asa guidelines for glp 1 The 2023 position on GLP-1 receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on GLP-1 RA guidance roundup -
Description
Recent shortages have frustrated patients, proving that logistics are as critical as innovation
Scheme 3
It feels like your bodys working against you, not with you
Together, these operational foundations are essential to reliably move oral GLP-1s from clinical promise to global commercial supply
The distinction between evidence-based pharmaceutical GLP-1 medications and unregulated patch products is critical for patient safety and treatment efficacy
